Beta-thalassemia (BT) intermedia is a form of BT characterized by mild to moderate anemia which does not or only occasionally requires transfusion.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on beta-thalassemia intermedia is limited primarily due to its relatively low prevalence and the variability in clinical presentation among affected individuals. Because this condition affects fewer than 10,000 people in the U.S., comprehensive clinical studies and systematic documentation have been challenging. The absence of established genetic markers further complicates the understanding of this condition, making it difficult to gather consistent data.
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Currently, there are 96 active clinical trials related to beta-thalassemia intermedia. These trials may explore various treatment options and management strategies, although no orphan drugs have been designated for this specific condition. For more information on ongoing research and to explore potential participation, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=beta-thalassemia%20intermedia.
Actionable guidance for navigating care for beta-thalassemia intermedia
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on beta-thalassemia intermedia is limited primarily due to its relatively low prevalence and the variability in clinical presentation among affected individuals. Because this condition affects fewer than 10,000 people in the U.S., comprehensive clinical studies and systematic documentation have been challenging. The absence of established genetic markers further complicates the understanding of this condition, making it difficult to gather consistent data.
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Currently, there are 96 active clinical trials related to beta-thalassemia intermedia. These trials may explore various treatment options and management strategies, although no orphan drugs have been designated for this specific condition. For more information on ongoing research and to explore potential participation, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=beta-thalassemia%20intermedia.
Actionable guidance for navigating care for beta-thalassemia intermedia
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on beta-thalassemia intermedia is limited primarily due to its relatively low prevalence and the variability in clinical presentation among affected individuals. Because this condition affects fewer than 10,000 people in the U.S., comprehensive clinical studies and systematic documentation have been challenging. The absence of established genetic markers further complicates the understanding of this condition, making it difficult to gather consistent data.
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Currently, there are 96 active clinical trials related to beta-thalassemia intermedia. These trials may explore various treatment options and management strategies, although no orphan drugs have been designated for this specific condition. For more information on ongoing research and to explore potential participation, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=beta-thalassemia%20intermedia.
Actionable guidance for navigating care for beta-thalassemia intermedia
To navigate your care for beta-thalassemia intermedia, consider seeking a hematologist with expertise in blood disorders, particularly those specializing in thalassemias. While no specific patient organizations are currently identified, you can find valuable resources through the Genetic and Rare Diseases (GARD) Information Center at rarediseases.info.nih.gov. Additionally, inquire about participation in clinical trials, which can provide access to new treatments and contribute to research efforts. Genetic counseling may also be beneficial, especially if there are concerns about family planning or genetic risks.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 2 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.